Navigation Links
AnaptysBio Awarded U.S. Government Contract To Develop Anti-Ricin Antibodies

SAN DIEGO, May 16, 2013 /PRNewswire/ -- AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced the receipt of a contract award from the U.S. government for the development of highly thermostable anti-ricin antibodies for biodefense applications.  Under the terms of AnaptysBio's contract with the Science and Technology Corporation, AnaptysBio will be responsible for delivering anti-ricin antibodies to the Edgewood Chemical and Biological Center (ECBC), an agency of the U.S. Army.  This contract is funded by the Defense Threat Reduction Agency (DTRA), and follows successful completion of multiple biodefense-related antibody programs by AnaptysBio in partnership with the Defense Advanced Research Projects Agency (DARPA). 


The Company's antibody platform, known as SHM-XEL, is uniquely positioned to generate highly potent, functional antibodies for therapeutic and diagnostic uses.  Utilizing a proprietary antibody scaffold in conjunction with SHM-XEL, AnaptysBio has recently published the development of multiple full-length antibodies with unprecedented thermostability properties.   Extended stability at room temperature conditions minimizes the cold chain dependency of AnaptysBio's antibodies, which is a competitive advantage in the production, distribution and storage of therapeutic and diagnostic products.  

AnaptysBio's primary focus is to develop a pipeline of novel therapeutic antibodies for unmet medical needs in cancer immunotherapy, inflammation, muscle wasting disorders, fibrosis and antibody drug conjugate applications.  In addition, AnaptysBio is exploring new opportunities for antibodies in diagnostics and veterinary uses.

"We are pleased to expand our relationship with the U.S. government to address emerging biodefense priorities," said Hamza Suria , president & chief executive officer of AnaptysBio. "The speed and technical advantages of our SHM-XEL technology platform continue to attract new partnerships.  Our platform's features have permitted AnaptysBio to rapidly develop a differentiated internal product pipeline against emerging targets of interest to pharma." 

About AnaptysBio

Founded in 2005, AnaptysBio, Inc. is a privately-held company focused on the generation of antibody therapeutics, and the leader in the use of somatic hypermutation (SHM) for antibody discovery and optimization. AnaptysBio's proprietary SHM-XEL platform, which couples fully human antibody libraries with in vitro somatic hypermutation (SHM) in mammalian cells to generate high affinity lead candidates, replicates key features of the human immune system and overcomes limitations of prior antibody technologies.  By harnessing the natural mechanism of antibody maturation under controlled conditions, SHM-XEL allows for the selection of optimal antibody properties such as high affinity, function, cross-reactivity, epitope diversity and manufacturability. AnaptysBio has established broad intellectual property around the use of SHM and is currently building a pipeline of novel therapeutic antibody product candidates, including differentiated programs in cancer immunotherapy, inflammation, muscle wasting disorders, fibrosis and antibody-drug conjugate applications. The Company has previously announced pharma partnerships with Merck, Roche, Novartis, Celgene, Gilead and DARPA.  Major investors in AnaptysBio include Alloy Ventures, Avalon Ventures, Frazier Healthcare Ventures and Novo A/S.  For more information, visit

SOURCE AnaptysBio, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AnaptysBio Develops Novel Antibody Scaffold With Extreme Thermostability
2. Anaptysbio Expands Leadership Team With Addition Of Dr. Andrew J. Mcknight
3. Aegis Awarded 2nd Patent for Fast Acting Migraine Nasal Spray Treatment
4. BidMed Awarded Equipment Liquidation and Related Services Agreement with the Premier Healthcare Alliance
5. Instrumentation Laboratory Awarded Massachusetts Life Sciences Center Tax Incentive
6. Dr. Isaac Eliaz Awarded Patent for Modified Citrus Pectin and Alginates
7. Creabilis Awarded Prestigious European Commission FP7 Grant to Further Develop its LSE Topical-by-Design Technology
8. Combat Medical Systems Awarded $86 Million DOD Contract
9. Remedium Technologies Inc. Awarded $500,000 Phase II NSF SBIR Grant to Test Sprayable Foam for Stopping Traumatic Bleeding
10. CCS Medical Awarded Medicare Contract
11. GE alliance awarded contract to design new plant-based manufacturing facility in Brazil
Post Your Comments:
(Date:11/26/2015)... 2015 ... the  "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Competitive Intelligence, ... --> ) has ... Future Horizons and Growth Strategies in ...
(Date:11/26/2015)... Research and Markets ( ) has announced the ... Type (Dressings, Therapy Devices, Active Wound Care), Application (Surgical ... Geography - Global Forecast to 2020" report to ... --> The purpose of this report is to ... advanced wound care market. It involves deep dive analysis ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... of the "Self Administration of High Viscosity ... ) has announced the addition of ... report to their offering. --> ... the addition of the "Self Administration of ...
Breaking Medicine Technology:
(Date:11/28/2015)... CA (PRWEB) , ... November 28, 2015 , ... Pixel ... fully customizable media panels to choose from, the possibilities are endless. Users have full ... more. With the ProPanel: Pulse masking effects, users are sure to get heads to ...
(Date:11/27/2015)... Los Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... new study carried out by the University of Toronto and the University of British ... number of hospitalizations for head injuries. The article explains that part of the reason ...
(Date:11/27/2015)... ... 2015 , ... A team of Swiss doctors has released a report on ... just posted the findings on the website. Click here to read the details ... mesothelioma patients who were treated with chemotherapy followed by EPP surgery. Among the 106 ...
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced a special promotion ... off of their purchase of lice treatment product. In addition, customers will receive a ... company spokesperson. “Finding lice is a sure way to ruin the holidays, so we ...
(Date:11/27/2015)... LOS ANGELES, CA (PRWEB) , ... November 27, 2015 , ... MPWH, the No.1 Herpes-only ... age of 30 (see Table 1-1 ). More than 3.7 billion people under ... simplex virus type 1 (HSV-1), according to WHO's first global estimates of HSV-1 infection ...
Breaking Medicine News(10 mins):